

Switzerland's Tillotts Pharma AG launches ulcerative colitis drug in China

July 29, 2021 | News

The commercial launch of Asacol[®] 800 mg tablets will bring new treatment options in a tablet formulation to clinicians



Tillotts Pharma AG ("Tillotts"), part of the Japanese Zeria Group, announced that the recent launch of Asacol[®] 800 mg tablets (mesalazine) as first-line treatment for mild to moderate ulcerative colitis (UC) in the People's Republic of China.

After announcing the successful partnership of Tillotts and Menarini in October 2019, and regulatory approval of Asacol[®] 800 mg in April 2020, the launch of the tablets represents a major milestone for both companies. The introduction of this high strength mesalazine tablet formulation to the Chinese market is expected to optimise the therapeutic options of patients living with UC in China.

Mattias Norrman, Chief Operations Officer at Tillotts, said, "launch of Asacol[®] in China has been achieved through the close partnership between Tillotts and Menarini and the efforts and continued dedication of the teams involved. Providing the highest strength mesalazine tablet in the Chinese market may help improve patient adherence to chronic ulcerative colitis treatment."